ReviewThe World Allergy Organization journal2023

Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL.

Francesco Menzella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.